X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
USFDA approved generic version of Levetiracetam for the treatment of seizures. It prevents seizure activity via the selective inhibition of hypersynchronized epileptiform burst firing without affecting normal neuronal transmission.
Lead Product(s): Levetiracetam
Therapeutic Area: Neurology Product Name: Keppra-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
Levetiracetam tablet is belongs to a class of drugs known as anticonvulsants, is indicated for adjunctive therapy in the treatment of Partial onset seizures in patients one month of age and older with epilepsy.
Lead Product(s): Levetiracetam
Therapeutic Area: Neurology Product Name: Keppra-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
ADX71149 (JNJ-40411813) is a novel orally active positive allosteric modulator of metabotropic Glutamate 2 receptor (mGlu2R). It is being developed for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Addex Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg.
Lead Product(s): Levetiracetam
Therapeutic Area: Neurology Product Name: Elepsia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tripoint Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
